Hypertension, or high blood pressure, is a major risk factor for heart disease and
stroke (
1
). The prevalence of hypertension is higher among men than among women, increases
with age, is highest among non-Hispanic blacks (blacks) (
2
), and has been consistently highest in the Southeastern region of the United States
(
1
). To update prevalence estimates for self-reported hypertension and use of antihypertensive
medication, CDC analyzed data from the 2017 Behavioral Risk Factor Surveillance System
(BRFSS). The overall (unadjusted) prevalence of self-reported hypertension was 32.4%
(95% confidence interval [CI] = 32.1%–32.7%). The age-standardized, median state-specific
prevalence of self-reported hypertension was 29.7% (range = 24.3%–38.6%). Overall
age-standardized hypertension prevalence was higher among men (32.9%) than among women
(27.0%), highest among blacks (40.0%), decreased with increasing levels of education
and household income, and was generally highest in the Southeastern and Appalachian
states.* Among persons reporting hypertension, the overall unadjusted prevalence of
self-reported antihypertensive medication use was 76.0% (95% CI = 75.5%–76.4%). The
age-standardized, median state-specific prevalence of antihypertensive medication
use among persons with reported hypertension was 59.4% (range = 50.2%–71.2%). Prevalence
was higher among women than men, highest among blacks compared with other racial/ethnic
groups, and highest among states in the Southeast, Appalachia, and the Dakotas. These
findings can help inform CDC’s initiatives to enhance hypertension awareness, treatment,
and control across all states.
BRFSS
†
is an annual, random-digit–dialed telephone survey (both landline and mobile phone),
representative of the noninstitutionalized adult population aged ≥18 years of the
50 states, the District of Columbia (DC), and U.S. territories. In 2017, a total of
450,016 adults were interviewed. The present study includes data from the 50 states
and DC; the median response rate was 45.9% (range = 30.6%–64.1%).
§
Respondents were classified as having hypertension if they answered “yes” to the question
“Have you ever been told by a doctor, nurse, or other health professional that you
have high blood pressure?” Those with borderline and pregnancy-related hypertension
were categorized as “no.” Respondents reporting hypertension were classified as currently
taking antihypertensive medication if they answered “yes” to the question “Are you
currently taking medicine for your high blood pressure?” All analyses incorporated
methods to account for the complex survey design. Application of sampling weights
accounted for nonresponse, noncoverage, and mobile telephone–only households, and
were derived from an iterative proportional weighting (raking) procedure.
¶
The unadjusted, age-specific, and age-standardized prevalence of self-reported hypertension
and antihypertensive medication use were estimated overall, for each of the 50 states
and DC, and by sociodemographic characteristics. Prevalence estimates were age-standardized
to the 2000 U.S. standard population (
3
). Differences in prevalence across sociodemographic subgroups were tested using chi-squared
tests, and differences reported were considered statistically significant for p-values
<0.05. All analyses were conducted using SAS-callable SUDAAN (version 11.0.3; RTI
International).
During 2017, the overall unadjusted prevalence of hypertension for the 50 states and
DC was 32.4% (95% CI = 32.1%–32.7%), representing an estimated 81.7 million adults
(Table 1). The age-standardized median state-specific prevalence of hypertension was
29.7% (range = 24.3% [Minnesota] to 38.6% [Alabama and West Virginia]). Age-standardized
hypertension prevalences were generally highest in Southeastern and Appalachian states
(Figure). Age-specific hypertension prevalence increased with increasing age group
(Table 2). The age-standardized prevalence of hypertension was higher among men (32.9%)
than among women (27.0%), highest among blacks (40.0%), and decreased with increasing
levels of education and household income.
TABLE 1
Unadjusted and age-standardized* prevalence of self-reported hypertension (HTN)
†
and current antihypertensive medication use
§
among adults aged ≥18 years — Behavioral Risk Factor Surveillance System, 50 U.S.
states and the District of Columbia, 2017
Area
Hypertension
Current antihypertensive medication use among adults with hypertension
Sample with HTN
Population with HTN (x 1,000)¶
% (95% CI)
Sample using antihypertensive medication
Population using antihypertensive medication (x 1,000)¶
% (95% CI)
Unadjusted
Age-standardized*
Unadjusted
Age-standardized*
Overall
178,312
81,674
32.4 (32.1–32.7)
29.9 (29.6–30.2)
146,754
61,927
76.0 (75.5–76.4)
59.6 (58.8–60.3)
State
Alabama
3,435
1,582
41.9 (40.3–43.4)
38.6 (37.1–40.1)
2,954
1,281
81.1 (79.1–83.1)
70.5 (67.1–73.9)
Alaska
1,245
176
31.8 (29.2–34.5)
31.8 (29.4–34.2)
875
113
64.4 (59.8–69.0)
53.0 (46.7–59.2)
Arizona
6,005
1,655
30.7 (29.8–31.5)
28.0 (27.1–28.8)
4,891
1,236
74.8 (73.2–76.3)
56.0 (53.6–58.4)
Arkansas
2,892
949
41.4 (39.0–43.7)
38.5 (36.1–40.8)
2,547
754
79.6 (76.5–82.8)
69.3 (64.2–74.4)
California
2,854
8,647
28.4 (27.1–29.6)
27.0 (25.9–28.1)
2,060
6,141
71.1 (68.8–73.4)
53.0 (50.0–56.0)
Colorado
3,189
1,130
26.0 (24.9–26.9)
24.8 (23.8–25.7)
2,395
764
69.9 (67.8–72.0)
52.7 (49.6–55.8)
Connecticut
3,991
859
30.5 (29.3–31.6)
27.2 (26.1–28.3)
3,313
658
76.8 (74.8–78.9)
57.3 (54.0–60.6)
Delaware
1,683
263
34.9 (32.9–36.9)
31.1 (29.2–33.0)
1,367
203
77.3 (74.2–80.4)
58.8 (53.5–64.1)
District of Columbia
1,505
149
26.4 (24.8–28.1)
28.2 (26.7–29.6)
1,241
111
74.5 (71.3–77.8)
61.7 (57.3–66.0)
Florida
9,360
5,810
34.6 (33.2–36.0)
29.7 (28.5–31.0)
7,568
4,496
77.5 (75.5–79.5)
58.3 (54.8–61.7)
Georgia
2,520
2,624
33.1 (31.6–34.6)
31.6 (30.2–33.0)
2,153
2,042
77.9 (75.4–80.3)
62.7 (59.0–66.4)
Hawaii
2,657
343
30.6 (29.2–32.0)
28.1 (26.9–29.4)
2,067
257
75.0 (72.5–77.4)
57.9 (54.3–61.5)
Idaho
1,806
379
29.8 (28.1–31.5)
27.5 (26.0–29.0)
1,378
260
69.0 (65.8–72.0)
50.2 (46.2–54.2)
Illinois
2,190
3,187
32.2 (30.8–33.7)
29.9 (28.5–31.3)
1,788
2,410
75.7 (73.3–78.2)
59.8 (55.4–64.1)
Indiana
6,226
1,796
35.2 (34.2–36.3)
32.6 (31.7–33.6)
5,262
1,372
76.5 (74.8–78.2)
60.4 (57.8–63.0)
Iowa
2,906
762
31.5 (30.3–32.6)
28.3 (27.3–29.4)
2,384
589
77.5 (75.5–79.4)
60.7 (57.4–64.0)
Kansas
8,757
718
32.8 (32.0–33.5)
30.5 (29.8–31.2)
7,187
544
75.8 (74.6–77.1)
59.2 (57.3–61.2)
Kentucky
4,214
1,356
39.4 (37.7–41.0)
36.1 (34.6–37.6)
3,600
1,094
80.8 (78.7–82.9)
67.5 (64.1–70.9)
Louisiana
2,208
1,400
39.0 (37.3–40.7)
36.8 (35.2–38.4)
1,849
1,123
80.3 (78.0–82.5)
69.0 (65.3–72.6)
Maine
3,909
376
34.8 (33.4–36.2)
29.9 (28.5–31.3)
3,117
279
74.5 (72(2–76.9)
56.5 (52.7–60.8)
Maryland
5,982
1,522
32.4 (31.2–33.5)
29.8 (28.7–30.9)
5,179
1,211
79.7 (77.8–81.5)
62.6 (59.1–66.1)
Massachusetts
2,475
1,564
28.6 (26.8–30.3)
25.7 (24.3–27.2)
2,053
1,220
78.1 (75.2–81.0)
59.7 (54.4–65.0)
Michigan
4,397
2,697
34.7 (33.6–35.8)
31.3 (30.3–32.3)
3,625
2,067
76.7 (75.0–78.4)
59.4 (56.5–62.2)
Minnesota
5,533
1,134
26.6 (25.8–27.4)
24.3 (23.5–25.0)
4,492
861
76.0 (74.3–77.6)
58.0 (55.3–60.5)
Mississippi
2,621
926
40.8 (38.8–42.7)
38.2 (36.4–40.0)
2,314
750
81.0 (78.3–83.8)
71.2 (66.8–75.5)
Missouri
3,133
1,513
32.0 (30.6–33.4)
29.0 (27.7–30.3)
2,671
1,204
79.7 (77.4–82.0)
64.0 (59.8–68.0)
Montana
2,211
238
29.0 (27.5–30.5)
25.7 (24.2–27.1)
1,750
170
71.8 (68.8–74.7)
51.7 (47.5–56.0)
Nebraska
5,895
443
30.6 (29.5–31.7)
28.2 (27.3–29.2)
4,957
348
78.6 (76.8–80.4)
61.5 (58.3–64.7)
Nevada
1,471
757
32.6 (30.5–34.8)
30.0 (28.1–32.0)
1,149
548
72.5 (68.9–76.2)
55.1 (49.2–61.1)
New Hampshire
2,284
324
30.0 (28.4–31.6)
25.9 (24.4–27.4)
1,915
257
79.7 (77.0–82.3)
62.2 (56.0–68.3)
New Jersey
4,897
2,305
33.0 (31.6–34.4)
30.1 (28.8–31.4)
4,096
1,750
76.0 (73.7–78.4)
58.3 (54.7–62.0)
New Mexico
2,496
484
30.5 (29.0–32.0)
28.0 (26.6–29.4)
1,952
353
73.2 (70.5–75.8)
57.1 (52.9–61.3)
New York
4,329
4,574
29.4 (28.3–30.5)
27.1 (26.2–28.1)
3,485
3,449
75.6 (73.7–77.5)
57.4 (54.6–60.2)
North Carolina
2,002
2,775
34.7 (33.0–36.5)
31.8 (30.2–33.3)
1,662
2,217
80.0 (77.6–82.5)
64.1 (59.9–68.4)
North Dakota
2,813
173
29.5 (28.2–30.8)
28.2 (27.0–29.4)
2,401
135
78.2 (75.9–80.6)
63.2 (59.2–67.3)
Ohio
5,394
3,130
34.7 (33.5–35.9)
31.4 (30.2–32.6)
4,618
2,433
77.9 (75.9–79.9)
61.5 (58.3–64.6)
Oklahoma
3,176
1,124
37.7 (36.2–39.2)
35.4 (34.0–36.7)
2,719
874
77.8 (75.6–80.0)
64.0 (60.6–67.5)
Oregon
1,835
987
30.1 (28.7–31.5)
27.2 (25.9–28.5)
1,374
699
71.0 (68.4–73.5)
53.3 (49.5–57.0)
Pennsylvania
2,337
3,295
32.6 (31.1–34.1)
28.9 (27.6–30.2)
1,896
2,586
78.6 (76.4–80.9)
60.9 (56.9–64.8)
Rhode Island
2,303
280
33.1 (31.4–34.8)
29.9 (28.3–31.5)
1,969
226
81.0 (78.4–83.7)
65.5 (60.3–70.6)
South Carolina
5,632
1,498
38.1 (36.9–39.3)
34.4 (33.3–35.6)
4,916
1,206
80.6 (78.9–82.4)
68.5 (65.2–71.8)
South Dakota
2,862
203
30.8 (28.9–32.7)
28.0 (26.2–29.7)
2,420
161
79.4 (76.3–82.5)
64.8 (59.0–70.5)
Tennessee
2,638
2,012
38.7 (36.9–40.4)
35.5 (33.9–37.2)
2,210
1,580
78.6 (76.0–81.1)
65.0 (60.9–69.1)
Texas
5,299
6,853
32.5 (30.8–34.2)
31.9 (30.3–33.5)
4,446
4,958
72.4 (69.4–75.3)
57.5 (53.5–61.6)
Utah
3,044
534
24.5 (23.4–25.5)
25.4 (24.5–26.4)
2,224
359
67.4 (65.1–69.7)
52.3 (49.6–55.1)
Vermont
2,313
153
30.4 (28.9–31.9)
26.4 (25.1–27.8)
1,804
112
73.5 (71.0–76.1)
51.7 (47.8–55.6)
Virginia
3,895
2,136
32.4 (31.1–33.6)
30.3 (29.1–31.5)
3,245
1,613
75.7 (73.5–77.9)
58.3 (55.1–61.5)
Washington
4,840
1,700
29.5 (28.6–30.5)
27.6 (26.6–28.5)
3,696
1,184
69.9 (68.0–71.7)
54.5 (51.9–57.2)
West Virginia
2,769
631
43.5 (28.6–30.5)
38.6 (37.0–40.2)
2,380
502
79.6 (77.5–81.7)
61.7 (58.4–65.1)
Wisconsin
2,143
1,387
30.8 (29.2–32.4)
27.9 (26.4–29.4)
1,743
1,041
75.4 (72.6–78.2)
57.0 (52.4–61.5)
Wyoming
1,741
138
30.8 (29.2–32.4)
28.5 (27.0–30.0)
1,397
98
71.7 (68.8–74.7)
53.5 (49.4–57.6)
Median
—
—
32.2
29.7
—
—
76.7
59.4
Range
—
—
24.5–43.5
24.3–38.6
—
—
64.4–81.1
50.2–71.2
Abbreviation: CI = confidence interval.
* Age standardized to the 2000 U.S. projected population using three age groups: 18–44,
45–64, and ≥65 years.
† Hypertension was defined as an affirmative response to “Have you ever been told
by a doctor, nurse, or other health professional that you have high blood pressure?”
Preeclampsia or borderline high or prehypertensive was categorized as “no.”
§ Current antihypertensive medication use was defined as affirmative response to “Are
you currently taking medicine prescribed by a doctor or other health professional
for your high blood pressure?”
¶ Weighted number of adults in the population with hypertension or currently using
antihypertensive medication.
FIGURE
Age-standardized percentage of self-reported hypertension and antihypertensive medication
use among adults aged ≥18 years, by state — Behavioral Risk Factor Surveillance System,
United States, 2017
Abbreviation: DC = District of Columbia.
The figure is two maps of the United States showing the age-standardized percentage
of self-reported hypertension and antihypertensive medication use among adults aged
≥18 years, by state, using data from the Behavioral Risk Factor Surveillance System,
2017.
TABLE 2
Unadjusted and age-standardized* prevalence of self-reported hypertension (HTN)
†
and antihypertensive medication use
§
among adults aged ≥18 years, by selected characteristics — Behavioral Risk Factor
Surveillance System, United States, 2017
Characteristic
Hypertension
Antihypertensive medication use among adults with hypertension
Sample with HTN
Population with HTN (x 1000)¶
% (95% CI)
Sample using antihypertensive medication
Population using antihypertensive medication (x 1,000)¶
% (95% CI)
Unadjusted
Age-standardized*
Unadjusted
Age-standardized*
Overall
178,312
81,674
32.4 (32.1–32.7)
29.9 (29.6–30.2)
146,754
61,927
76.0 (75.5–76.4)
59.6 (58.8–60.3)
Age group (yrs)
18–44
18,432
16,429
14.1 (13.7–14.5)
14.1 (13.8–14.5)
7,512
6,195
37.9 (36.5–39.2)
37.9 (36.5–39.2)
45–64
66,699
34,048
40.5 (40.0–41.0)
40.5 (40.0–41.0)
53,783
27,085
79.6 (78.9–80.3)
79.6 (78.9–80.3)
≥65
93,181
31,198
60.5 (60.0–61.1)
60.5 (60.0–61.1)
85,459
28,647
92.0 (91.5–92.4)
92.0 (91.5–92.4)
Sex*
Men
81,648
42,260
34.5 (34.0–34.9)
32.9 (32.5–33.3)
64,010
30,136
71.5 (70.7–72.2)
56.7 (55.8–57.6)
Women
96,569
39,363
30.4 (30.0–30.8)
27.0 (26.6–27.3)
82,669
31,747
80.8 (80.1–81.4)
64.0 (62.7–65.2)
Race/Ethnicity*
White, non-Hispanic
136,668
53,179
34.0 (33.7–34.3)
29.0 (28.7–29.3)
113,525
41,278
77.7 (77.2–78.2)
59.0 (58.1–59.9)
Black, non-Hispanic
18,628
12,127
41.1 (40.1–42.1)
40.0 (39.2–40.9)
16,116
9,649
79.6 (78.3–80.9)
68.1 (66.2–70.0)
Hispanic
9,081
9,510
23.9 (23.0–24.7)
28.2 (27.3–29.1)
6,359
6,133
64.8 (62.8–66.8)
54.0 (51.9–56.0)
American Indian/Alaska Native, non-Hispanic
3,624
976
38.8 (36.4–41.3)
37.1 (34.7–39.5)
2,784
690
70.7 (66.7–74.7)
58.6 (53.6–63.5)
Asian, non-Hispanic
2,290
2,659
19.6 (17.8–21.4)
23.8 (21.9–25.8)
1,786
1,835
69.2 (64.5–73.9)
58.0 (52.8–63.0)
Native Hawaiian/Pacific Islander, non-Hispanic
316
127
26.4 (21.2–31.7)
33.0 (28.3–38.0)
200
87
68.4 (59.1–77.6)
54.9 (45.8–63.6)
Multiracial, non-Hispanic
3,373
1,060
30.1 (28.3–32.0)
31.6 (29.9–33.4)
2,504
731
69.1 (65.9–72.3)
56.7 (52.8–60.6)
Other, non-Hispanic
880
368
33.1 (28.8–37.3)
28.9 (25.3–32.8)
703
276
75.2 (67.9–82.5)
54.9 (45.4–64.0)
Education level*
Less than high school
15,316
13,232
39.1 (38.1–40.2)
35.4 (34.4–36.3)
12,605
10,020
75.9 (74.4–77.4)
58.6 (56.4–60.8)
High school or equivalent
54,498
24,742
35.2 (34.6–35.7)
32.3 (31.8–32.8)
45,423
18,944
76.7 (75.9–77.6)
59.6 (58.4–60.9)
More than high school
107,886
43,411
29.5 (29.2–29.9)
27.5 (27.2–27.8)
88,234
32,756
75.6 (74.9–76.2)
59.8 (58.8–60.8)
Household income*
<$15,000
17,836
9,145
40.7 (39.6–41.8)
37.9 (36.9–39.0)
14,384
6,889
75.5 (73.9–77.1)
61.5 (59.3–63.7)
$15,000 to <$25,000
28,614
13,017
36.9 (36.1–37.7)
34.3 (33.6–35.1)
23,605
9,895
76.1 (74.9–77.4)
59.7 (57.9–61.5)
$25,000 to <$35,000
17,502
7,731
35.5 (34.5–36.6)
31.9 (30.9–32.9)
14,589
5,928
76.8 (75.3–78.4)
60.4 (57.5–63.2)
$35,000 to <$50,000
22,129
9,213
33.1 (32.3–34.0)
29.9 (29.1–30.7)
18,451
7,029
76.4 (75.0–77.8)
56.9 (54.9–58.8)
≥$50,000
61,667
29,012
28.2 (27.8–28.7)
26.9 (26.5–27.3)
49,890
21,529
74.3 (73.5–75.1)
59.7 (58.5–60.9)
Abbreviation: CI = confidence interval.
*Age standardized to the 2000 U.S. projected population using three age groups: 18–44,
45–64, and ≥65 years.
† Hypertension was defined as an affirmative response to “Have you ever been told
by a doctor, nurse, or other health professional that you have high blood pressure?”
Preeclampsia or borderline high or pre-hypertensive was categorized as “no.”
§ Current antihypertensive medication use was defined as affirmative response to “Are
you currently taking medicine prescribed by a doctor or other health professional
for your high blood pressure?”
¶ Weighted number of adults in the population with hypertension or currently using
antihypertensive medication.
Among those reporting hypertension, the overall, unadjusted prevalence of antihypertensive
medication use was 76.0% (95% CI = 75.5%–76.4%), representing an estimated 61.9 million
adults (Table 1). The age-standardized, median, state-specific prevalence of antihypertensive
medication use was 59.4% (range = 50.2% [Idaho] to 71.2% [Mississippi]). Age-standardized
prevalence of antihypertensive medication use was highest in the Southeastern and
Appalachian states, as well as the Dakotas (Figure). The age-specific prevalence of
antihypertensive medication use also increased with increasing age (Table 2), was
highest among blacks (68.1%), was higher among women (64.0%) than among men (56.7%),
and did not vary by education or household income level.
Discussion
During 2017, approximately one third (82 million) of U.S. adults reported having hypertension,
and an estimated three quarters of those with hypertension (62 million) reported using
antihypertensive medication. Age-standardized prevalence of hypertension varied widely
by state, remaining highest in the Southeast and among men and blacks. Age-standardized
prevalence of antihypertensive medication use also increased with increasing age,
was highest among blacks, and was higher among women than among men.
The overall age-standardized self-reported hypertension prevalence of 29.9% was similar
to that reported based on 2011–2015 BRFSS data (29.8%) (
1
) and measured hypertension prevalence of 29% based on data from the 2015–2016 National
Health and Nutrition Examination Survey (
2
). Also consistent with other reports, hypertension prevalence decreased with increasing
income (
4
) and education level (
1
) and was highest in Southeastern and Appalachian states (
1
,
2
). The overall, age-standardized prevalence of antihypertensive medication use (59.6%)
was also similar to estimates from the 2011–2015 BRFSS, ranging from 63.0% in 2011
to 61.8% in 2015 (
1
). Like hypertension prevalence, medication use prevalence was highest in Southeastern
and Appalachian states. In the present study, prevalence of medication use was also
highest in the Dakotas, despite a midrange prevalence of hypertension in these states.
Prevalence of antihypertensive medication use was higher in older age groups, highest
among blacks, and higher among women than men. This overall gender difference has
been reported previously (
1
), but the reasons are unclear. Data from Medicare Part D beneficiaries aged ≥65 years
suggest that antihypertensive medication nonadherence is similar for men (25.8%) and
women (26.7%) (
5
). More information is needed to examine the relationship between the prevalence of
self-reported hypertension and that of antihypertensive medication use.
The findings in this report are subject to at least three limitations. First, data
were self-reported. The lack of documented diagnosis of hypertension based on historic
blood pressure measurements does not allow for precise assessment of hypertension;
however, the results were similar to data from previous reports based on both self-report
(
1
) and measured hypertension (
2
). Second, low median response rates across states might limit the representativeness
of the 2017 BRFSS sample and potentially result in either under- or overestimates
of prevalence, although application of sampling weights is likely to reduce some nonresponse
bias. Finally, findings are representative of noninstitutionalized civilian persons
only and would exclude those living in nursing homes, prisons, and other institutions.
This report provides the most recent state-level surveillance data on prevalence of
self-reported hypertension and antihypertensive medication use among persons reporting
hypertension. Hypertension prevention and control is a priority of CDC’s state and
local funding for heart disease and stroke prevention** and one of the important elements
of the Million Hearts initiative (
6
). CDC has been working closely with states to enhance hypertension management through
a strategy of team-based care in which two or more health care providers work collaboratively
with each patient. These teams may include doctors, nurses, pharmacists, dietitians,
community health workers, and other health care providers. This approach is often
multidisciplinary with a team working to educate patients, identify risk factors,
provide treatments, and sustain ongoing conversations with patients. This strategy
can result in multiple opportunities for intervention for better blood pressure control
(
7
),
††
with the ultimate goal of reducing disparities in hypertension awareness, treatment,
and control across the United States.
Summary
What is already known about this topic?
Prevalence of hypertension increases with increasing age and is higher among men than
women and among non-Hispanic blacks than among other racial/ethnic groups; prevalence
has been consistently higher in the Southeastern and Appalachian regions of the United
States.
What is added by this report?
Analysis of 2017 Behavioral Risk Factor Surveillance System data found that approximately
one third of U.S. adults reported having hypertension, and an estimated 75% of those
reporting having hypertension reported using antihypertensive medication. The prevalence
of these factors varied widely by state and was generally highest in the Southeastern
and Appalachian states.
What are the implications for public health practice?
A multidisciplinary team-based strategy working to educate patients, maintain dialogue
over time, and identify risk factors can provide intervention opportunities for better
blood pressure control and could reduce disparities in hypertension awareness, treatment,
and control across the United States.